About Influenza Vaccine Influenza is an infectious disease caused by the influenza virus. It is also known as flu. Influenza virus is a ribonucleic acid (RNA) virus that belongs to Orthomyxoviridae family. It is a helical shaped, single-stranded virus. Influenza A virus affects people of all age groups and causes moderate to severe illness, while the infection due to influenza B virus results in milder disease and affects pediatrics primarily. Human illness due to influenza C is rare. Influenza C illness might be due to subclinical cases. Hence, it does not cause epidemic diseases. Influenza has emerged as a severe health concern globally. The market encompasses both live attenuated as well as recombinant influenza vaccines for the prevention of influenza. The major factors that lead to the market growth include the need for annual vaccination and government initiatives to improve awareness about vaccination. Technavio’s analysts forecast the global influenza vaccine market to grow at a CAGR of 7.23% during the period 2018-2022. Covered in this report The report covers the present scenario and... Research Beam Model: Research Beam Product ID: 2867512 3500 USD New
Global Influenza Vaccine Market 2018-2022
 
 

Global Influenza Vaccine Market 2018-2022

  • Category : Healthcare
  • Published On : January   2018
  • Pages : 113
  • Publisher : Technavio
 
 
 
About Influenza Vaccine
Influenza is an infectious disease caused by the influenza virus. It is also known as flu. Influenza virus is a ribonucleic acid (RNA) virus that belongs to Orthomyxoviridae family. It is a helical shaped, single-stranded virus. Influenza A virus affects people of all age groups and causes moderate to severe illness, while the infection due to influenza B virus results in milder disease and affects pediatrics primarily. Human illness due to influenza C is rare. Influenza C illness might be due to subclinical cases. Hence, it does not cause epidemic diseases. Influenza has emerged as a severe health concern globally. The market encompasses both live attenuated as well as recombinant influenza vaccines for the prevention of influenza. The major factors that lead to the market growth include the need for annual vaccination and government initiatives to improve awareness about vaccination.

Technavio’s analysts forecast the global influenza vaccine market to grow at a CAGR of 7.23% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the global influenza vaccine market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of influenza vaccine.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Influenza Vaccine Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• AstraZeneca
• CSL
• GlaxoSmithKline
• Sanofi
Other prominent vendors
• Altimmune
• BionVax
• FluGen
• FOLIA BIOTECH
• Genentech
• Green Cross
• Medicago
• Moderna Therapeutics
• Novavax
• Shijiazhuang Yiling Pharmaceutical
• SK Chemicals
• UNM Pharma
• Vaccitech
• Vaxart
• Vaxine Pty
• Visterra.
Market driver
• Rising awareness about influenza vaccination
• For a full, detailed list, view our report

Market trend
• Development of strong pipeline
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2022 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?


You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
• Market outline
PART 05: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 06: MARKET SIZING
• Market definition
• Market sizing 2017
• Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 08: PIPELINE LANDSCAPE
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
• Overview
• Comparison by vaccine type
• Global live attenuated influenza vaccines market
• Global recombinant influenza vaccines market
• Market opportunity by vaccine type
PART 10: MARKET SEGMENTATION BY AGE GROUP
• Adults
• Pediatrics
PART 11: CUSTOMER LANDSCAPE
PART 12: REGIONAL LANDSCAPE
• Geographical segmentation
• Regional comparison
• Influenza vaccine market in Americas
• Influenza vaccine market in EMEA
• Influenza vaccine market in APAC
• Market opportunity
PART 13: DECISION FRAMEWORK
PART 14: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 15: MARKET TRENDS
• Strong pipeline
• Strategic alliances
PART 16: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 17: VENDOR ANALYSIS
• Overview
• Vendor classification
• Market positioning of vendors
• AstraZeneca
• CSL
• GlaxoSmithKline
• Sanofi
PART 18: APPENDIX
• List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global vaccine market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition: Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global influenza vaccine market 2017-2022 ($ millions)
Exhibit 09: Global influenza vaccine market: Year-over-year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition: Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials candidates of influenza vaccines
Exhibit 20: Global influenza vaccine market by vaccine type 2017-2022 (%)
Exhibit 21: Comparison by vaccine type
Exhibit 22: Global live attenuated influenza vaccines market 2017-2022 ($ millions)
Exhibit 23: Global live attenuated influenza vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 24: Global recombinant influenza vaccines market 2017-2022 ($ millions)
Exhibit 25: Global recombinant influenza vaccines market: Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by vaccine type
Exhibit 27: Adult influenza vaccine products and their cost
Exhibit 28: Pediatric influenza vaccine products and their cost
Exhibit 29: Customer landscape
Exhibit 30: Global influenza vaccine market by geography 2017-2022 (%)
Exhibit 31: Regional comparison
Exhibit 32: Influenza vaccine market in Americas 2017-2022 ($ millions)
Exhibit 33: Influenza vaccine market in Americas: Year-over-year growth 2018-2022 (%)
Exhibit 34: Top 3 countries in Americas
Exhibit 35: Influenza vaccine market in EMEA 2017-2022 ($ millions)
Exhibit 36: Influenza vaccine market in EMEA: Year-over-year growth 2018-2022 (%)
Exhibit 37: Top 3 countries in EMEA
Exhibit 38: Influenza vaccine market in APAC 2017-2022 ($ millions)
Exhibit 39: Influenza vaccine market in APAC: Year-over-year growth 2018-2022 (%)
Exhibit 40: Top 3 countries in APAC
Exhibit 41: Market opportunity
Exhibit 42: Distribution of influenza vaccine doses in US by season
Exhibit 43: Steps for production of IIV
Exhibit 44: Molecules in phase III with sponsors
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendor landscape
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: AstraZeneca: Overview
Exhibit 51: AstraZeneca: Business segments
Exhibit 52: AstraZeneca: Organizational developments
Exhibit 53: AstraZeneca: Geographic focus
Exhibit 54: AstraZeneca: Segment focus
Exhibit 55: AstraZeneca: Key offerings
Exhibit 56: AstraZeneca: Key customers
Exhibit 57: CSL: Overview
Exhibit 58: CSL: Business segments
Exhibit 59: CSL: Organizational developments
Exhibit 60: CSL: Geographic focus
Exhibit 61: CSL: Segment focus
Exhibit 62: CSL: Key offerings
Exhibit 63: CSL: Key customers
Exhibit 64: GlaxoSmithKline: Overview
Exhibit 65: GlaxoSmithKline: Business segments
Exhibit 66: GlaxoSmithKline: Organizational developments
Exhibit 67: GlaxoSmithKline: Geographic focus
Exhibit 68: GlaxoSmithKline: Segment focus
Exhibit 69: GlaxoSmithKline: Key offerings
Exhibit 70: GlaxoSmithKline: Key customers
Exhibit 71: Sanofi: Overview
Exhibit 72: Sanofi: Business segments
Exhibit 73: Sanofi: Organizational developments
Exhibit 74: Sanofi: Geographic focus
Exhibit 75: Sanofi: Segment focus
Exhibit 76: Sanofi: Key offerings
Exhibit 77: Sanofi: Key customers

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT